Methyl-C-L-methionine Positron Emission Tomography for Radiotherapy Planning for Recurrent Malignant Glioma

Overview

Journal Ann Nucl Med

Date 2024 Feb 15

PMID 38356008

Authors

Hikaru Niitsu

Nobuyoshi Fukumitsu

Keiichi Tanaka

Masashi Mizumoto

Kei Nakai

Masahide Matsuda

Eiichi Ishikawa

Kentaro Hatano

Tsuyoshi Hashimoto

Satoshi Kamizawa

Hideyuki Sakurai

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate differences in uptake regions between methyl-C-L-methionine positron emission tomography (C-MET PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI), and their impact on dose distribution, including changing of the threshold for tumor boundaries.

Methods: Twenty consecutive patients with grade 3 or 4 glioma who had recurrence after postoperative radiotherapy (RT) between April 2016 and October 2017 were examined. The study was performed using simulation with the assumption that all patients received RT. The clinical target volume (CTV) was contoured using the Gd-enhanced region (CTV(Gd)), the tumor/normal tissue (T/N) ratios of C-MET PET of 1.3 and 2.0 (CTV (T/N 1.3), CTV (T/N 2.0)), and the PET-edge method (CTV(P-E)) for stereotactic RT planning. Differences among CTVs were evaluated. The brain dose at each CTV and the dose at each CTV defined by C-MET PET using MRI as the reference were evaluated.

Results: The Jaccard index (JI) for concordance of CTV (Gd) with CTVs using C-MET PET was highest for CTV (T/N 2.0), with a value of 0.7. In a comparison of pixel values of MRI and PET, the correlation coefficient for cases with higher JI was significantly greater than that for lower JI cases (0.37 vs. 0.20, P = 0.007). D50% of the brain in RT planning using each CTV differed significantly (P = 0.03) and that using CTV (T/N 1.3) were higher than with use of CTV (Gd). V90% and V95% for each CTV differed in a simulation study for actual treatment using CTV (Gd) (P = 1.0 × 10 and 3.0 × 10, respectively) and those using CTV (T/N 1.3) and CTV (P-E) were lower than with CTV (Gd).

Conclusions: The region of C-MET accumulation is not necessarily consistent with and larger than the Gd-enhanced region. A change of the tumor boundary using C-MET PET can cause significant changes in doses to the brain and the CTV.

References

Lee I, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J . Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2008; 73(2):479-85. PMC: 2652133. DOI: 10.1016/j.ijrobp.2008.04.050. View

Mineura K, Sasajima T, Suda Y, Kowada M, Shishido F, Uemura K . Amino acid study of cerebral gliomas using positron emission tomography--analysis of (11C-methyl)-L-methionine uptake index. Neurol Med Chir (Tokyo). 1990; 30(13):997-1002. DOI: 10.2176/nmc.30.997. View

Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim M . Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9):1199-208. PMC: 4999003. DOI: 10.1093/neuonc/now058. View

Ullrich R, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H . Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009; 50(12):1962-8. DOI: 10.2967/jnumed.109.065904. View

Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View

Jacobs A, Thomas A, Kracht L, Li H, Dittmar C, Garlip G . 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005; 46(12):1948-58. View

Navarria P, Pessina F, Clerici E, Bellu L, Franzese C, Franzini A . Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. Radiother Oncol. 2021; 167:89-96. DOI: 10.1016/j.radonc.2021.12.019. View

Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F . Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006; 104(2):238-53. DOI: 10.3171/jns.2006.104.2.238. View

Miwa K, Matsuo M, Ogawa S, Shinoda J, Yokoyama K, Yamada J . Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiat Oncol. 2014; 9:181. PMC: 4155106. DOI: 10.1186/1748-717X-9-181. View

10.

Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C . Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003; 30(11):1561-7. DOI: 10.1007/s00259-003-1259-1. View

11.

Iuchi T, Hatano K, Uchino Y, Itami M, Hasegawa Y, Kawasaki K . Methionine Uptake and Required Radiation Dose to Control Glioblastoma. Int J Radiat Oncol Biol Phys. 2015; 93(1):133-40. DOI: 10.1016/j.ijrobp.2015.04.044. View

12.

Kinoshita M, Hashimoto N, Goto T, Yanagisawa T, Okita Y, Kagawa N . Use of fractional anisotropy for determination of the cut-off value in 11C-methionine positron emission tomography for glioma. Neuroimage. 2008; 45(2):312-8. DOI: 10.1016/j.neuroimage.2008.11.034. View

13.

Jung T, Min J, Bom H, Jung S, Kim I, Lim S . Prognostic value of post-treatment metabolic tumor volume from C-methionine PET/CT in recurrent malignant glioma. Neurosurg Rev. 2016; 40(2):223-229. DOI: 10.1007/s10143-016-0748-1. View

14.

Navarria P, Reggiori G, Pessina F, Ascolese A, Tomatis S, Mancosu P . Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiother Oncol. 2014; 112(3):425-9. DOI: 10.1016/j.radonc.2014.09.004. View

15.

Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N . 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg. 2018; 131(3):676-686. DOI: 10.3171/2018.4.JNS1859. View

16.

Kinoshita M, Goto T, Arita H, Okita Y, Isohashi K, Kagawa N . Imaging ¹⁸F-fluorodeoxy glucose/¹¹C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema. J Neurooncol. 2011; 106(2):417-25. DOI: 10.1007/s11060-011-0688-0. View

17.

Whitfield G, Kennedy S, Djoukhadar I, Jackson A . Imaging and target volume delineation in glioma. Clin Oncol (R Coll Radiol). 2014; 26(7):364-76. DOI: 10.1016/j.clon.2014.04.026. View

18.

Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins V, Bergstrom M . Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol. 1989; 30(3):225-32. View

19.

Chung J, Kim Y, Kim S, Lee Y, Paek S, Yeo J . Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002; 29(2):176-82. DOI: 10.1007/s00259-001-0690-4. View

20.

Galldiks N, Niyazi M, Grosu A, Kocher M, Langen K, Law I . Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro Oncol. 2021; 23(6):881-893. PMC: 8168815. DOI: 10.1093/neuonc/noab013. View